Heterogeneity in terms of tumor characteristics, prognosis, and survival among cancer patients has been a persistent problem for many decades. Currently, prognosis and outcome predictions are made based on clinical factors and/or by incorporating molecular profiling data.
INTRODUCTION
Over the past three decades, remarkable improvement has been achieved in cancer treatment in the United States, with the annual death rate from cancer declining 1.4% for women, 1.8% for men, and 2.3% for children ages 0-10 years from 2002 to 2011 (EDWARDS et al. 2014) .
However, the problem that has persisted in cancer treatment is the heterogeneity of prognostic prediction across patients (BARILLOT 2013 ). This heterogeneity is, for the most part, genetically determined and rooted in the molecular profile of patients. A Precision medicine initiative has been introduced by White House to expand cancer genomics research as a short-term goal to develop better prevention and treatment methods for more cancers (COLLINS and VARMUS 2015) .
survival, proliferation and metastatic dissemination (BARILLOT 2013; HUANG et al. 2014) . Based on the observation that multiple genes in the same biological processes appear to be dysfunctional regardless of cancer type, gene pathways information is likely a more robust biological phenomenon (BILD et al. 2006) . Various public databases (e.g., KEGG) can be accessed online or in R package to provide the biological information about pathways which may provide valuable improvement to prognosis and prediction (KANEHISA and GOTO 2000) . Thus methods incorporating higher-order information of functional units in cancer, i.e., pathways, have been the focus of recent investigations (JONES 2008; JONES et al. 2008; LEE et al. 2008; REYAL et al. 2008; ABRAHAM et al. 2010; TESCHENDORFF et al. 2010; ENG et al. 2013; HUANG et al. 2014) . Among those previous studies, Abraham et al. adopted a gene set statistic to provide stability of prognostic signatures instead of individual genes (ABRAHAM et al. 2010) . Huang et al.
converted the gene matrix to a pathway matrix through "principal curve", similar to principal components analysis (HUANG et al. 2014) . Both of these two methods did not incorporate outcome when generating the pathways scores from the individual genes. Other sophisticated statistical methods have been developed for variable selection with grouped predictors or pathways using an "all-in-all-out" idea, meaning that when one predictor in a group is chosen, then all variables in that group are chosen (PARK et al. 2007; WEI and LI 2007; JONES 2008) .
Other methods that could address the above shortcomings have also been developed, however, leading to increased computational complexity and potentially instability of models when the number of predictors is large (HUANG et al. 2009; ZHOU 2010; ENG et al. 2013) . Eng et al. (2013) proposed a method to reduce the computational complexity by incorporating a binary outcome to stand for decreased or increased risk score in each pathway which inferred potentially loss of information.
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Breast cancer is the second most commonly diagnosed malignancy after skin cancer in women (HUANG et al. 2014) . It is estimated to be the third leading cause of cancer death after lung cancer and rectal/colon cancer in 2015 (NCI 2015) . It is widely understood that breast cancer can be categorized into four clinical subtypes: Luminal A, Luminal B, Triple Negative/Basal like and Her2 and the survival/metastasis outcomes differ significantly among these four subtypes (CAREY et al. 2006; O'BRIEN et al. 2010; HAQUE et al. 2012) . However, it is increasingly being realized that using only the clinical subtypes cannot discriminate breast cancers patients, and that better prediction of prognosis is needed. The breast cancer data set from TCGA includes ~20000 genes mapped into 109 pathways for 505 patients. The results show that the proposed approach not only improves survival prediction compared with the alternative analysis that ignores the pathway information, but also identifies significant biological pathways.
METHODS

Cox proportional hazards models
The copyright holder for this preprint (which was not . http://dx.doi.org/10.1101/043661 doi: bioRxiv preprint first posted online Mar. 15, 2016;  Cox regression is the commonly used method for analyzing censored survival data (VAN HOUWELINGGEN and PUTTER 2012) , for which the hazard function of survival time T takes the form:
where 0 ( ) h t is the baseline hazard function, X and β are the vectors of predictors and coefficients, respectively, and X β is the linear predictor or called the prognostic index. The coefficients β are estimated by maximizing the partial log-likelihood: Ridge, lasso and elastic-net Cox models. The elastic net is a widely used penalization approach to handle high-dimensional models, which adds the elastic-net penalty to the loglikelihood function and estimates the parameters β by maximizing the penalized loglikelihood (ZOU and HASTIE 2005; HASTIE et al. 2009; FRIEDMAN et al. 2010; SIMON et al. 2011; HASTIE et al. 2015) . For the Cox models described above, we estimate the parameters β by maximizing the penalized partial log-likelihood:
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The ridge, lasso and elastic net Cox models can be fitted by the cyclic coordinate descent algorithm, which successively optimizes the penalized log-likelihood over each parameter with others fixed and cycles repeatedly until convergence. The cyclic coordinate descent algorithm has been implemented in the R package glmnet. The package glmnet can quickly fit the elasticnet Cox models over a grid of values of λ covering the entire range, giving a sequence of models for users to choose from. Cross-validation is the most widely used method to select an optimal value λ (e.g., an optimal Cox model) that gives minimum cross-validated error.
Bayesian hierarchical Cox model. hierarchical model is an efficient approach to handling high-dimensional data, where the regression coefficients are themselves modeled (GELMAN and HILL 2007; GELMAN et al. 2014) . Hierarchical models are more easily interpreted and handled in the Bayesian framework where the distribution of the coefficient is the prior distribution, and statistical inference is based on the posterior estimation. The commonly used prior is the double-exponential (or Laplace) prior distribution (PARK and CASELLA 2008; YI and XU 2008; YI and MA 2012) :
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Relation of hierarchical Cox model to the Lasso
The Lasso is equivalent to hierarchical Cox model with the double-exponential prior 
is the estimate of β from all the data except the k-th part, (RAPPAPORT 2007; BOVELSTAD et al. 2009; JACOB 2009; ZHANG et al. 2013; YUAN et al. 2014; ZHAO et al. 2014 ). However, due to highdimension of genomic data, fitting one model including all genes can lead to instability of peer-reviewed) is the author/funder. All rights reserved. No reuse allowed without permission.
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Here we used an two-stage procedure for combining multiple pathways to build a prediction model, inspired by the super learner of van der Laan et al. (2007) (VAN DER LAAN et al. 2007 ; VAN HOUWELINGEN and PUTTER 2011) . The two-stage procedure for building the prognostic model by combining multiple biological pathways is presented in Figure 1 .
(Insert Figure 1 here , for each individual. To prevent overfitting, instead of calculating the prognostic indices directly, we estimated cross-validated prognostic scores using leave-one-out cross-validation (LOOCV). The prognostic scores were calculated for i-th testing set using the parameters
In the second stage, we combine the cross-validated prognostic scores from all pathways as new predictors to build a super prognostic model for prediction:
. 10-fold cross-validation over 10 repeats was used to evaluate the predictive performance of the super prognostic model.
Evaluating the predictive performance
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Data Preprocessing
54 samples were removed for missing or zero overall survival time. 17815 features across 533 samples were profiled for gene expression, which includes a total of 1571 missing observations. Simple imputation with mean values across samples was adopted to fill the missing values. For further analysis, only 505 samples were kept for whom survival time and gene expression were both available. Among these 505 patients, only 65 were dead and thus the event rate was 12.9%.
Pathway Analysis
To construct the pathways, we used genome annotation tools, KEGG (KANEHISA and GOTO 2000) , to map genes to pathways. After mapping gene symbols to Entrez ids, 17252 probes were kept. We mapped all the probes to KEGG pathways using the R annotation package RDAVIDWebService (FRESNO and FERNANDEZ 2013) . 3181 probes were mapped to 109 pathways.
Two-Stage Approach for integrating pathways
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The predictive performance of the models was also assessed by Brier scores. Figure 1 shows the Brier prediction errors for two-stage hierarchical-hierarchical Cox Model ( Table 3 .
(Insert Figure 3 and Table 3 here)
Risk Group Stratification
In order to demonstrate the potential for using two-stage approach to stratify patients into risk groups, we split the patients by the median of the cross-validated prognostic scores into two groups. Those patients with cross-validated prognostic score greater than the median were categorized as low-risk group; while patients with cross-validated prognostic score less than the median were categorized as high-risk group. The Kaplan-Meier curves for low-risk and high-risk (Insert Figure 4 here) peer-reviewed) is the author/funder. All rights reserved. No reuse allowed without permission.
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DISCUSSION
The heterogeneity of prognostic prediction in cancers has been a persisted problem for decades (BARILLOT 2013) . It is now realized that cancer is a fundamentally disease of genome and can be understood by identifying the abnormal genes and proteins that are associated with the risk of developing cancer. Some statistical and machine learning methods have been used to analyze genomic data with gene-based approach to search for gene signature and to predict prognosis (RAPPAPORT 2007; BOVELSTAD et al. 2009; JACOB 2009; ZHANG et al. 2013; YUAN et al. 2014; ZHAO et al. 2014) (GOEMAN and BUHLMANN 2007; LEE et al. 2008; REYAL et al. 2008; ABRAHAM et al. 2010; TESCHENDORFF et al. 2010) .
Our two-stage approach is developed to incorporate the functional structure of pathways to predict survival for cancer patients. Different from some previous methods that summarize pathway score using only gene information or positive/negative signs, our method incorporates the correlation with survival information in the calculating individual pathway information.
Besides, we use cross-validated prognostic score as pathway score to be used in the second stage, which not only prevents overfitting and can be easily carried out, but also gives an unbiased view on the contribution of the different information from pathways to the prediction model. Our Our approach is also capable of identifying core pathways in cancer. Mitogen-activated protein kinase (MAPK) pathways are important in controlling fundamental cellular processes, i.e.
growth, proliferation, differentiation, migration and apoptosis (DHILLON et al. 2007 ). When abnormally activated, MAPK pathways can lead to the progression of cancer (USSAR and VOSS 2004; MCCUBREY et al. 2007) . Another pathway, the mammalian target of rapamycin (mTOR), also plays an essential role in the regulation of cell proliferation, growth, differentiation, migration and survival. Similarly to MAPK pathways, the dysregulation of mTOR signaling happens in various human tumors, resulting in higher susceptibility to inhibitors of mTOR peer-reviewed) is the author/funder. All rights reserved. No reuse allowed without permission.
The HUANG and HOUGHTON 2003) . The Hedgehog pathway regulates many fundamental processes including stem cell maintenance, cell differentiation, tissue polarity and cell proliferation. It has been demonstrated that inappropriate activation of Hedgehog pathway occurs in various cancers such as brain, gastrointestinal, lung, breast and prostate cancers (GUPTA et al. 2010) .
Furthermore, the JAK-STAT pathway is also identified in our approach. This pathway regulates in various cellular processes such as stem cell maintenance, apoptosis and the inflammatory response and was found frequently dysregulated in diverse types of cancer (THOMAS et al. 2015) .
However, there are some potential limitations in this method. We implemented our approach only in microarray gene expression data from TCGA breast cancer project. There are many other platforms in gene expression data, such as RNA-Seq data. It may require additional constraints for the RNA-Seq data to be implemented into the model. Another potential limitation is that only 3181 mapped genes among the nearly 20000 expressed genes were fitted in the model, suggesting potentially loss of gene information.
Despite the above potential limitations, our two-stage pathway-based approach performs better in predicting overall survival of breast cancer and is able to identify important cancer pathways. In the future, we will apply our approach in other levels of genomic data, e.g. DNA methylation, miRNA and copy number alterations, for more than 30 types of cancer. We will also continue to develop more efficient ways to combine different levels of genomic data as well as clinical biomarkers into our proposed method to better predict cancer survival.
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